CBD investments death or growth?

There is a lot of controversial articles we are reading on the net about FDA’s decision to treat CBD products as potential drugs. All the implication show interest to support the transparent activities for Drug Master File and all GxP aspects as if it was a normal, regular medicine. We stand-by this initiative, because we feel safe and confident with all legal and quality measures FDA is getting its hands on for this kind of products.